1. A pharmaceutical composition containing the polymorph E N- (3 - {[((2Z) -3 - [(2-chloro-5-methoxyphenyl) amino] quinoxaline-2 (1H) -ilidene] sulfamoyl} phenyl) -2-methylalaninamide hydrogel polymer and diluent. 2. The pharmaceutical composition of claim 1, wherein the hydrogel is selected from the group consisting of microcrystalline cellulose, methyl cellulose, hydroxymethyl cellulose, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxides, gums, acrylate polymers and methac. The pharmaceutical composition of claim 1, wherein the hydrogel is microcrystalline cellulose. The pharmaceutical composition of claim 1, wherein the diluent is selected from the group consisting of sugars, starches, vegetable oils, lactose monohydrate, calcium phosphate, dextrin, dextrose, maltitol, maltose, starch, sucrose and talc. The pharmaceutical composition of claim 1, wherein the diluent is starch and the starch is pregelatinized starch or sodium starch glycolate. The pharmaceutical composition according to claim 1, containing, by weight, 40-60% polymorph E； 15-35% microcrystalline cellulose； 5-15% of pregelatinized starch and from 0.1 to 10.0% of each of hypromellose, silicon dioxide and sodium starch glycolate. 7. The pharmaceutical composition of claim 1, comprising, by weight, about 50% polymorph E； about 27% microcrystalline cellulose； about 10% pregelatinized starch, about 3% hypromellose, about 1% silicon dioxide, and about 4% sodium starch glycolate. 8. The pharmaceutical composition according to any one of paragraphs. 1-7, where the pharmaceutical composition is present in tablet form. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in the form of1. Фармацевтический состав, содержащий полиморф E N-(3-{[(2Z)-3-[(2-хлор-5-метоксифенил)амино]хиноксалин-2(1H)-илиден]сульфамоил}фенил)-2-метилаланинамида, гидрогелевый полимер и разбавитель.2. Фармацевтический состав по п. 1,
